TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22654944

Group type: EXPERIMENTAL
Intervention: Intervention (15 manualized sessions over 5 weeks of cognitive behavioral techniques and creative expressive elements)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 399

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 399
Study: 20590434

Group type: EXPERIMENTAL
Intervention: 6-session psychoeducative group therapy module
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19
Study: 19013336

Group type: COMPARATOR
Intervention: Liposomal amphotericin B (L‐AmB) 3 mg/kg/day
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (L‐AmB) 10 mg/kg/day
Number of subjects: 339
Study: 15804471

Group type: EXPERIMENTAL
Intervention: 75 mg of aspirin once a day for 14 days
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 300 mg of aspirin once a day for 14 days
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo tablet for 14 days
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: All groups (75 mg, 300 mg, and placebo)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 75 mg and 300 mg of aspirin
Number of subjects: 51
Study: 12860578

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1513

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1513

Group type: EXPERIMENTAL
Intervention: Baseline SBP
Number of subjects: 1513

Group type: EXPERIMENTAL
Intervention: Baseline DBP
Number of subjects: 1513
Study: 10375935

Group type: EXPERIMENTAL
Intervention: Iscador QuS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intron A (human recombinant interferon alpha)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 8669517

Group type: EXPERIMENTAL
Intervention: Intervention group (work site-based cancer prevention program)
Number of subjects: 28000

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28000
Study: 1518264

Group type: EXPERIMENTAL
Intervention: Continuous epinephrine infusion (0.01-0.02 mg/kg) started one hour before and finished one hour after the infusion of E. coli L-asparaginase
Number of subjects: 7
Study: 6472970

Group type: EXPERIMENTAL
Intervention: Palatal appliance with oroenteric tubes
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nasoenteric tubes (control group)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Removal of feeding tubes after several days
Number of subjects: 29
Study: 30296472

Group type: EXPERIMENTAL
Intervention: Eating As Treatment (EAT) intervention delivered by oncology dietitians
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Eating As Treatment (EAT) intervention
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 307
Study: 30307410

Group type: EXPERIMENTAL
Intervention: Tacrolimus plus a single, intraoperative, high-dose (9 mg/kg) rabbit anti-T-lymphocyte globulins (ATLG)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Tacrolimus monotherapy (TAC)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Tacrolimus plus ATLG
Number of subjects: 206
Study: 26977624

Group type: EXPERIMENTAL
Intervention: Remaxol (400 ml intravenously, 2 times a day for 7 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline with 25%-magnesium sulfate (10 ml) and 4% potassium chloride (10 ml)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remaxol
Number of subjects: 80
Study: 23680491

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 63
Study: 22699165

Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study: 20825615

Group type: EXPERIMENTAL
Intervention: 20 mL/kg perfluorocarbon
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 30 mL/kg perfluorocarbon
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 40 mL/kg perfluorocarbon
Number of subjects: 24
Study: 17879531

Group type: EXPERIMENTAL
Intervention: Migu Tablet group (MGTG)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Xianlin Gubao group (XLGBG)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Leli Calcium group (LCG)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study: 16372237

Group type: EXPERIMENTAL
Intervention: Routine enema procedures prior to delivery (264 subjects)
Number of subjects: 534

Group type: COMPARATOR
Intervention: No enema (270 subjects)
Number of subjects: 534
Study: 12376205

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin 70 mg/m² (days 1, 8, 15, 29, 36, 43) in combination with escalating doses of paclitaxel (225 mg/m² 4-weekly or 100 mg/m² weekly)
Number of subjects: 49
Study: 10102059

Group type: COMPARATOR
Intervention: 0.1 IU/kg/day (0.03 mg/kg/day), administered once daily (Group A)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 0.2 IU/kg/day (0.07 mg/kg/day), administered once daily (Group B)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 0.2 IU/kg/day (0.07 mg/kg/day), divided into two equal injections given at 12‐hour intervals (Group C)
Number of subjects: 92
Study: 7794869

Group type: EXPERIMENTAL
Intervention: Test meal A
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Test meal B
Number of subjects: 9
Study: 2221415

Group type: EXPERIMENTAL
Intervention: 10% Intralipid (3 mL/min for 20 min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 5% dextrose in lactated Ringer's solution
Number of subjects: 60
Study: 348222

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.1 mg and Morphine 10 mg with Droperidol 2.5 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.1 mg and Morphine 10 mg with Droperidol 5.0 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Fentanyl 0.1 mg and Morphine 10 mg (without Droperidol)
Number of subjects: 240
Study: 30144600

Group type: EXPERIMENTAL
Intervention: Virtual reality preoperative planning
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional preoperative planning
Number of subjects: 30
Study: 28486087

Group type: EXPERIMENTAL
Intervention: Simulator group (LapSim® VR simulator with haptic feedback)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 26016870

Group type: EXPERIMENTAL
Intervention: MFGM diet (whipping cream, 40 g milk fat/d)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control diet (butter oil, 40 g milk fat/d)
Number of subjects: 57
Study: 23436260

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study: 20594878

Group type: EXPERIMENTAL
Intervention: Lidocaine (3 mg/kg/h) and Ketamine (0.6 mg/kg/h) with Morphine (0.24 mg/kg/h)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Lidocaine (3 mg/kg/h) and Ketamine (0.6 mg/kg/h) with Fentanyl (0.0036 mg/kg/h)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ringer's lactate solution (Control)
Number of subjects: 44
Study: 19621198

Group type: EXPERIMENTAL
Intervention: Ornithine alpha-ketoglutarate (OKG) 10g daily
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ornithine alpha-ketoglutarate (OKG)
Number of subjects: 160
Study: 17293085

Group type: COMPARATOR
Intervention: Mecamylamine (MEC) 0.0 mg/day
Number of subjects: 53

Group type: COMPARATOR
Intervention: Mecamylamine (MEC) 5.0 mg/day
Number of subjects: 53

Group type: COMPARATOR
Intervention: Mecamylamine (MEC) 10.0 mg/day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Acute smoking abstinence
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Baseline smoking measures
Number of subjects: 53
Study: 15573355

Group type: EXPERIMENTAL
Intervention: Surface-derived autogenous bone graft
Number of subjects: 193
Study: 16990657

Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Diet (VLCD) for 4 days (1.6 MJ)
Number of subjects: 16
Study: 10364862

Group type: EXPERIMENTAL
Intervention: AutoGuard cannula (group AG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional Insyte intravenous cannula (group C)
Number of subjects: 100
Study: 8759372

Group type: EXPERIMENTAL
Intervention: Soy protein isolate beverage powder (60 g/d for 28 d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Casein supplement
Number of subjects: 20
Study: 2007444

Group type: EXPERIMENTAL
Intervention: 2 mg of Prostaglandin E2 (PGE2) administered by intravaginal route in a hydroxyethyl cellulose gel medium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7124678

Group type: EXPERIMENTAL
Intervention: Low O2 regimen
Number of subjects: 23

Group type: COMPARATOR
Intervention: High O2 regimen
Number of subjects: 23
Study: 31048444

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate solution (4.2 g in 50 mL of 50 mmol/L) with standard preoperative infusion of normal saline (1.5 L)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Placebo (50 mL) with standard preoperative infusion of normal saline (1.5 L)
Number of subjects: 478
Study: 29402762

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention promoting healthy eating habits and physical activities (12-month duration, includes in-person educational sessions and digital communication via website and text messages)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 315
Study: 27609408

Group type: EXPERIMENTAL
Intervention: benralizumab 30 mg Q4W
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: benralizumab 30 mg Q8W
Number of subjects: 1205

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1205
Study: 24606622

Group type: EXPERIMENTAL
Intervention: Online educational modules
Number of subjects: 0
Study: 22234043

Group type: EXPERIMENTAL
Intervention: Dairy consumption (highest quintile at 18 months)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Consumption of at least two dairy serves at both 18 months and 9 years
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Calcium, magnesium, and potassium intakes (highest quintiles)
Number of subjects: 335
Study: 19662418

Group type: EXPERIMENTAL
Intervention: MDCT with three-dimensional post-processing (3Ds)
Number of subjects: 145
Study: 18086760

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Regular aerobic and resistance exercise
Number of subjects: 242

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 242
Study: 15678363

Group type: EXPERIMENTAL
Intervention: Caffeine (75 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12118865

Group type: EXPERIMENTAL
Intervention: Concurrent auditory task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Driving-related scene elements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Driving-unrelated scene elements
Number of subjects: 0
Study: 10450639

Group type: EXPERIMENTAL
Intervention: Bionator with anterior extraoral traction and up-and-down elastics
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bionator and extraoral traction without additional securing of the mandible
Number of subjects: 20
Study: 7818116

Group type: EXPERIMENTAL
Intervention: Intravenous oxycodone (7.9 +/- 1.5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rectal oxycodone (30 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous oxycodone
Number of subjects: 12
Study: 2159694

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study: 30452645

Group type: EXPERIMENTAL
Intervention: Health Promoting Schools components adherence
Number of subjects: 61
Study: 29768119

Group type: EXPERIMENTAL
Intervention: Brigatinib (90 to 240 mg total daily) in phase I/II trial; 90 mg once daily in ALTA arm A; 180 mg once daily with 7-day lead-in at 90 mg in ALTA arm B.
Number of subjects: 79
Study: 26546241

Group type: EXPERIMENTAL
Intervention: High variety support exercise program for 6 weeks
Number of subjects: 121

Group type: COMPARATOR
Intervention: Low variety support exercise program for 6 weeks
Number of subjects: 121
Study: 24268433

Group type: EXPERIMENTAL
Intervention: Air-conducted (AC) stimulation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bone-conducted (BC) stimulation
Number of subjects: 20
Study: 23110515

Group type: EXPERIMENTAL
Intervention: Insecticide treated materials (ITMs) including PermaNet 2.0 netting treated with deltamethrin at 55 mg/m2 and targeted interventions (larviciding with Temephos, elimination of breeding sites)
Number of subjects: 970

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 970
Study: 20507292

Group type: EXPERIMENTAL
Intervention: Rituximab therapy (2.0 grams divided into two doses of 1.0 gram on days 1 and 15)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Methotrexate (not specified dosage or duration)
Number of subjects: 8
Study: 17143011

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan combined with 0.34% chlorhexidine dihydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.0% triclosan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference preparation containing fusidic acid
Number of subjects: 0
Study: 16320790

Group type: EXPERIMENTAL
Intervention: Progestin‐only injectable hormonal contraceptive Norethisterone oenanthate 200 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (non-users of progestin‐only injectable contraceptive)
Number of subjects: 50
Study: 11952201

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE) therapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Standard Exposure (SE) therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 49
Study: 9799042

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg)
Number of subjects: 90
Study: 7549332

Group type: EXPERIMENTAL
Intervention: 3.5 mm corneal tunnel incision
Number of subjects: 62

Group type: COMPARATOR
Intervention: 5 mm corneal tunnel incision
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 62
Study: 2693794

Group type: EXPERIMENTAL
Intervention: beta-methyldigoxin (medixin)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: bemecor (digicor)
Number of subjects: 81
Study: 358754

Group type: EXPERIMENTAL
Intervention: Clomipramine (50-125 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Amitriptyline (50-125 mg/day)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 72
Study: 30779375

Group type: EXPERIMENTAL
Intervention: fesoterodine (4 mg/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: mirabegron (50 mg/day)
Number of subjects: 120
Study: 29455482

Group type: EXPERIMENTAL
Intervention: Unilateral pedicle screw (UPS) after TLIF technique combined with contralateral percutaneous transfacet screw (PTS) fixation (group A)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Bilateral pedicle screws (BPS) fixation (group B)
Number of subjects: 46
Study: 25563584

Group type: EXPERIMENTAL
Intervention: FES-assisted cycling
Number of subjects: 50

Group type: COMPARATOR
Intervention: Passive cycling
Number of subjects: 50
Study: 23982939

Group type: EXPERIMENTAL
Intervention: CSE‐EVR (combined spinal-epidural anaesthesia) with 0.5 mg per 10 cm height of hyperbaric levobupivacaine and 20 microg fentanyl, followed by 20 mL saline solution injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: SA (single shot spinal anaesthesia)
Number of subjects: 60
Study: 21049267

Group type: EXPERIMENTAL
Intervention: THC (400 μg/kg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 mg/ml and 0.7 mg/ml)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combined effects of THC and alcohol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (0 mg/ml)
Number of subjects: 21
Study: 19968623

Group type: EXPERIMENTAL
Intervention: Satisfaction measured by a single question (Likert 5 scale)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Harris Hip Score
Number of subjects: 106
Study: 16256874

Group type: EXPERIMENTAL
Intervention: ICD therapy for ventricular tachycardia (VT) or ventricular fibrillation (VF)
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Interim hospitalization for congestive heart failure (IH-CHF)
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Interim hospitalization for coronary events (IH-CE)
Number of subjects: 719
Study: 12446291

Group type: EXPERIMENTAL
Intervention: Mini‐Mental State Examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sheffield Screening Test for Acquired Language Disorders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raven's Coloured Progressive Matrices
Number of subjects: 0
Study: 10515402

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline (1 mg q.i.d.)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Inhaled salbutamol (100, 100, 200 microg at 5 min intervals)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Budesonide (400 microg, b.i.d.)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 8787255

Group type: COMPARATOR
Intervention: Epidural corticosteroids (caudal or lumbar)
Number of subjects: 907

Group type: COMPARATOR
Intervention: Caudal epidural steroid
Number of subjects: 907

Group type: COMPARATOR
Intervention: Lumbar epidural steroid
Number of subjects: 907

Group type: COMPARATOR
Intervention: Epidural corticosteroids
Number of subjects: 907
Study: 1799922

Group type: EXPERIMENTAL
Intervention: Quinapril (10 to 20 mg daily)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Enalapril (10 to 20 mg daily)
Number of subjects: 53
Study: 6274473

Group type: EXPERIMENTAL
Intervention: Normal sodium diet in hypertensive patients
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal sodium diet in normotensive subjects
Number of subjects: 42
Study: 28643052

Group type: EXPERIMENTAL
Intervention: Spaced learning concept
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conservative training
Number of subjects: 20
Study: 26736024

Group type: EXPERIMENTAL
Intervention: TMT+NMES
Number of subjects: 64

Group type: COMPARATOR
Intervention: Passive control
Number of subjects: 64
Study: 25620554

Group type: EXPERIMENTAL
Intervention: Thera-band resistance exercise
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (routine activities)
Number of subjects: 95
Study: 23473338

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (to achieve a hemoglobin target of 13 g per deciliter)
Number of subjects: 2278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2278

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 2278
Study: 21917440

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate 500 μg (FP500) twice-daily
Number of subjects: 17
Study: 18455784

Group type: EXPERIMENTAL
Intervention: Activity monitoring
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Activity monitoring with a pedometer
Number of subjects: 125
Study: 16880485

Group type: EXPERIMENTAL
Intervention: Emotional ventilation debriefing
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Educational debriefing
Number of subjects: 236

Group type: COMPARATOR
Intervention: No debriefing (control)
Number of subjects: 236
Study: 15198477

Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day, n=9)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (n=9)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CAD group
Number of subjects: 26
Study: 11028729

Group type: EXPERIMENTAL
Intervention: Ropivacaine 3.75 mg/ml
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline 0.3 ml/kg
Number of subjects: 60
Study: 9298419

Group type: EXPERIMENTAL
Intervention: Phacoemulsification (PE)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Standard extracapsular cataract surgery
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Other ocular disease
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Intraoperative complications
Number of subjects: 375
Study: 8291628

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 111

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 111
Study: 3604970

Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharide (5 g tid for 12 d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sucrose (5 g tid for 12 d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharide (10 g)
Number of subjects: 15
Study: 30138384

Group type: EXPERIMENTAL
Intervention: Combined navigated laser photocoagulation and intravitreal ranibizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranibizumab monotherapy
Number of subjects: 0
Study: 27009936

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 490

Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 490
Study: 25201934

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy‐oriented anger management and stress control program (5 sessions, 90 minutes each)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard quit program
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy‐oriented anger management and stress control program
Number of subjects: 350
Study: 22675955

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Paracetamol 1 g
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 20029974

Group type: EXPERIMENTAL
Intervention: Celiac axis infusion chemotherapy combined with radiotherapy (CAI/RT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No adjuvant treatment (Control)
Number of subjects: 120
Study: 17468012

Group type: EXPERIMENTAL
Intervention: Perceptual priming during the incidental encoding phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptual priming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control words (not explicitly defined)
Number of subjects: 0